NASDAQ:NRIX Nurix Therapeutics (NRIX) Stock Price, News & Analysis $13.72 -0.38 (-2.72%) As of 01:20 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Nurix Therapeutics Stock (NASDAQ:NRIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Nurix Therapeutics alerts:Sign Up Key Stats Today's Range$13.71▼$14.3950-Day Range$14.10▼$27.2652-Week Range$13.65▼$28.23Volume697,263 shsAverage Volume1.75 million shsMarket Capitalization$1.50 billionP/E Ratio5.96Dividend YieldN/APrice Target$34.43Consensus RatingModerate Buy Company Overview Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California. Founded in 2009, it develops medicines that aim to treat cancer and other diseases by changing the levels of specific proteins inside cells. The company’s technology focuses on protein degradation, using the cell’s natural protein-disposal system to remove disease-related proteins. Nurix also researches ways to regulate protein activity through ubiquitin signaling, a process that helps control how proteins function and are broken down. Nurix’s pipeline includes investigational drug candidates, including BTK degraders being studied for B-cell cancers and candidates designed to affect immune-cell signaling. The company has also pursued research and development collaborations with pharmaceutical partners. Its medicines remain under investigation and are not established treatments.AI Generated. May Contain Errors. Read More Nurix Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreNRIX MarketRank™: 3.45880584779 of 5 starsNurix Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 399th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingNurix Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on no strong buy ratings, 14 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialNurix Therapeutics has a consensus price target of $34.43, representing about 145.7% upside from its current price of $14.01.Amount of Analyst CoverageNurix Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Nurix Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nurix Therapeutics are expected to decrease in the coming year, from $1.14 to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nurix Therapeutics is 6.13, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.89.Price to Earnings Ratio vs. SectorThe P/E ratio of Nurix Therapeutics is 6.13, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.25.Price to Book Value per Share RatioNurix Therapeutics has a P/B Ratio of 2.65. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nurix Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted18.58% of the float of Nurix Therapeutics has been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 7.17.Change versus previous monthShort interest in Nurix Therapeutics has recently decreased by 8.11%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNurix Therapeutics does not currently pay a dividend.Dividend GrowthNurix Therapeutics does not have a long track record of dividend growth. News and Social Media1.4 / 5News Sentiment0.28 News SentimentNurix Therapeutics has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Nurix Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 2 people have searched for NRIX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $893,645.00 in company stock.Percentage Held by Insiders6.70% of the stock of Nurix Therapeutics is held by insiders.Percentage Held by InstitutionsNurix Therapeutics has minimal institutional ownership at this time.Read more about Nurix Therapeutics' insider trading history. Receive NRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NRIX Stock News HeadlinesNurix Therapeutics, Inc. (NRIX) Presents at UBS Global Biopharma Conference 2026 TranscriptNovember 17 at 3:21 PM | seekingalpha.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Has Average Price Target of $34.43 According to BrokeragesNovember 17 at 2:33 AM | americanbankingnews.comCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savings account… The digital dollar is inevitable. Think about what this means... When the digital dollar goes live, every dollar you saved could suddenly be trackable at the transaction level. Imagine the worst case scenario: You’re now subject to new digital withdrawal limits and spending restrictions. Your account can be frozen remotely without court approval. But here's what Bank of America didn't say: There's still a way to protect your wealth before this digital prison locks. While everyone else gets trapped in the digital system, my research team has been positioning members outside that reach… completely under their own control. No government tracking. No withdrawal limits. No remote freezing.November 19 at 1:00 AM | Decentralized Masters (Ad)Nurix Appoints Arati Rao As Chief Medical Officer To Lead Clinical DevelopmentNovember 11, 2026 | rttnews.comNurix Therapeutics Appoints Arati V. Rao, M.D., as Chief Medical OfficerNovember 11, 2026 | globenewswire.comNurix Therapeutics to Participate in Upcoming Investor ConferencesNovember 10, 2026 | globenewswire.comInsider Selling: Nurix Therapeutics (NASDAQ:NRIX) CFO Sells 4,769 Shares of StockNovember 5, 2026 | insidertrades.comNurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 1,452 Shares of Company StockNovember 3, 2026 | insidertrades.comSee More Headlines NRIX Stock Analysis - Frequently Asked Questions How have NRIX shares performed this year? Nurix Therapeutics' stock was trading at $18.97 at the beginning of 2026. Since then, NRIX shares have decreased by 26.1% and is now trading at $14.01. How were Nurix Therapeutics' earnings last quarter? Nurix Therapeutics, Inc. (NASDAQ:NRIX) issued its earnings results on Tuesday, October, 13th. The company reported $4.73 earnings per share for the quarter, beating analysts' consensus estimates of ($0.60) by $5.33. The firm earned $673.06 million during the quarter, compared to the consensus estimate of $24.35 million. Nurix Therapeutics had a net margin of 42.01% and a trailing twelve-month return on equity of 49.34%. When did Nurix Therapeutics IPO? Nurix Therapeutics (NRIX) raised $187 million in an initial public offering on Friday, July 24th 2020. The company issued 11,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel served as the underwriters for the IPO and Needham & Company was co-manager. Who are Nurix Therapeutics' major shareholders? Top institutional shareholders of Nurix Therapeutics include State Street Corp (4.05%), Goldman Sachs Group Inc. (1.17%), Pictet Asset Management Holding SA (1.03%) and Soleus Capital Management L.P. (0.82%). Insiders that own company stock include Gwenn Hansen, Houte Hans Van, Christine Ring and Julia P Gregory. View institutional ownership trends. How do I buy shares of Nurix Therapeutics? Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nurix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nurix Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Tesla (TSLA), Vertex Pharmaceuticals (VRTX), NIO (NIO) and Uber Technologies (UBER). Company Calendar Last Earnings10/13/2026Today11/19/2026Fiscal Year End11/30/202638th Annual Healthcare Conference12/02/2026Next Earnings (Estimated)1/27/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, NRIX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:NRIX CIK1549595 Webwww.nurixtx.com Phone415-660-5320FaxN/AEmployees357Year Founded2012Price Target and Rating Average Price Target for Nurix Therapeutics$34.43 High Price Target$45.00 Low Price Target$20.00 Potential Upside/Downside+148.1%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)$2.31 Trailing P/E Ratio6.00 Forward P/E RatioN/A P/E GrowthN/ANet Income-$264.46 million Net Margins42.01% Pretax Margin43.91% Return on Equity49.34% Return on Assets38.61% Debt Debt-to-Equity RatioN/A Current Ratio8.44 Quick Ratio8.44 Sales & Book Value Annual Sales$701.94 million Price / Sales2.16 Cash FlowN/A Price / Cash FlowN/A Book Value$5.29 per share Price / Book2.62Miscellaneous Outstanding Shares109,250,000Free Float101,930,000Market Cap$1.52 billion OptionableOptionable Beta1.80 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:NRIX) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersDon’t delete this, read it todayPorter Stansberry has spent more than 30 years studying the economy and financial markets, and says he has nev...Porter & Company | SponsoredChase, Wells Fargo and Capital One all showed errors on Nov. 16On November 16, customers of Chase, Bank of America, Wells Fargo, Capital One and Zelle reported errors when t...Cedar Gold Group | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nurix Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.